Crescent Biopharma (CBIO) Capital Expenditures (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Capital Expenditures of $13000.0 for Q2 2026, down 90.71% year-over-year from $140000.0 in Q2 2025, and down 91.16% quarter-over-quarter from $147000.0 in Q1 2026.
Crescent Biopharma (CBIO) Capital Expenditures (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Capital Expenditures for 14 consecutive years, with $13000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures fell 90.71% year-over-year to $13000.0; the TTM figure through Jun 2026 stood at $939000.0 (up 570.71% YoY), while the FY2025 annual figure was $919000.0, up 9115.8% from the prior year.
- Capital Expenditures declined to $13000.0 in Q2 2026 per CBIO's latest filing, from $147000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $586000.0 in Q3 2025 and bottomed at $1.0 in Q4 2022.
- Historically, Capital Expenditures has averaged $79637.1 across 5 years, with a median of $10530.0 in 2023.
- Annual changes were most pronounced in 2022 — Capital Expenditures slumped 99.96% — and 2023, when it soared 80000.0%.
- Crescent Biopharma's Capital Expenditures stood at $1.0 in 2022, then jumped by 80000.0% to $801.0 in 2023, then surged by 216.23% to $2533.0 in 2024, then soared by 7519.42% to $193000.0 in 2025, then slumped by 93.26% to $13000.0 in 2026.
- Business Quant data shows CBIO's Capital Expenditures at $13000.0 in Q2 2026, $147000.0 in Q1 2026, and $193000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 13,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13,000.00 |
| Jun 30, 2026 | 13,000.00 |
| Mar 31, 2026 | 147,000.00 |
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | -75,000.00 |
| Dec 31, 2025 | -75,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Jun 30, 2024 | 2,533.00 |
| Jun 30, 2024 | 2,533.00 |
| Mar 31, 2024 | 7,439.00 |
| Mar 31, 2024 | 7,439.00 |
| Dec 31, 2023 | 801.00 |
| Dec 31, 2023 | 801.00 |
| Sep 30, 2023 | 7,866.00 |
| Sep 30, 2023 | 7,866.00 |
| Jun 30, 2023 | 10,530.00 |
| Jun 30, 2023 | 10,530.00 |